

THE LATIN AMERICAN ASSOCIATION OF SOCIETIES OF BIOLOGY AND NUCLEAR MEDICINE IS PLEASED TO INVITE YOU TO PARTICIPATE IN THE PRESENTATION OF ABSTRACTS FOR THE XXX CONGRESS OF ALASBIMN TO BE HELD FROM MARCH 13 TO 16, IN BENITO JUAREZ, QUINTANA ROO, MEXICO.

The awards will be granted according to the registered category. It is important for participants to indicate their intention to compete for an award. Each submission will be reviewed by the organizing committee.

PARTICIPATION GUIDELINES

1. All abstracts related to the following topics will participate:
 - I. Basic Sciences (Radiopharmacy, Chemistry, and Physics). “Dr. Jorge Varela”
 - II. Clinical PET in oncology (Researcher under 35 years). “Dr. Ernesto Lubin”
 - III. Researcher under 35 years (Radiopharmacy, Chemistry, and Physics). “Dr. Julio Cesar Kieffer”
 - IV. Neurology. “Dr. Ismael Mena”
 - V. Technologists. “Lic. FM. Mercedes Borron”
 - VI. Best Clinical Work. “Dr. Hugo Claire”
2. The abstracts must not have been previously published, and the authors must belong to a member country of ALASBIMN.
3. The abstracts must represent an original and significant contribution to Nuclear Medicine and Biology according to the registered category.
4. The abstract must be written in English or Spanish and must include:
 - a) Category for the competition
 - b) Title
 - c) Authors
 - d) Notation described: Last Name and First Name(s)

- e) Unit/affiliation
 - f) Email of the principal or corresponding author
 - g) Keywords
 - h) Introduction
 - i) Justification
 - j) Statement of the problem or research question
 - k) General objective
 - l) Materials and methods
 - m) Results
 - n) Discussion
 - o) Conclusions
 - p) Bibliographic references
 - q) Maximum length of 300 words (excluding title, authors, and references)
 - r) Arial 12-point font
 - s) No illustrations or tables.
5. The abstracts must be uploaded to the abstracts platform on the conference website: www.alasbimnmexico2025.com
The deadline to receive your abstracts will be December 15, 2024.
You should receive a confirmation; if you do not, please contact us.
6. Once the abstracts are received, the authors and their order of appearance cannot be modified.
7. The time, place, date, and hour of presentation will be assigned.
8. The work must be presented by one of the authors.
9. The Jury will be composed of full members of the Association/Federation as determined by the board.
10. Abstracts that include as authors members of the jury or board cannot compete.
11. The judging criteria will consider methodology, relevance, and scientific impact.

12. The jury's decision will be final.
13. The award may be declared void.
14. The award results will be announced during the closing of our congress.
15. Any situation not foreseen in this announcement will be resolved by the board of ALASBIMN and FMMNIM.
16. Deadline for submission of abstracts: **December 15, 2024.**
17. Deadline to receive acceptance for e-poster or oral presentation or rejection response for the abstract: **January 10, 2025.**
18. Upon receiving the acceptance letter, if accepted for an e-poster, you must upload your work in PDF format to the abstracts platform on the website www.alasbimnmexico2025.com according to the specifications published in that section. If accepted for an oral presentation, you must upload your work in PowerPoint format to the abstracts platform on the website www.alasbimnmexico2025.com, as well as an extended version in Word format according to the guidelines published on the website www.alasbimnjournal.net/informacion-para-autores. Failure to submit this will automatically exclude your participation. Submission deadline: **March 1, 2025.**
19. The prizes are described below according to their category:

- *Basic Sciences (Radiopharmacy, Chemistry, and Physics). "Dr. Jorge Varela"*

ARTICLE VIII: The prize will consist of a Diploma of Honor for Merit, which will be awarded to each of the authors.

- *Clinical PET in oncology (Researcher under 35 years). "Dr. Ernesto Lubin"*

The prize for the best work on Clinical Applications of PET in Oncology.

ARTICLE III: The principal author must be a maximum of 35 years old at the time of the award announcement.

ARTICLE IX: The prize will consist of a Diploma of Honor for Merit, awarded to each of the authors, and a prize of \$500 USD (five hundred US dollars) to the principal author under 35 years of age.

- *Researcher under 35 years (Radiopharmacy, Chemistry, and Physics). "Dr. Julio César Kieffer"*

The prize for the best Clinical or Basic work, whose principal researcher is under 35 years.

ARTICLE VIII: The prize will consist of a Diploma of Honor for Merit, awarded to

each of the authors.

- *Neurology. “Dr. Ismael Mena”*

ARTICLE VIII: The prize will consist of a Diploma of Honor for Merit, awarded to each of the authors.

- *Technologists. “Lic. FM. Mercedes Borrón”*

ARTICLE VIII: The prize will consist of a Diploma of Honor for Merit, awarded to each of the authors.

- *Best Clinical Work. “Dr. Hugo Claure”*

ARTICLE VIII: The prize will consist of a Diploma of Honor for Merit, awarded to each of the authors.

Additionally, the WFNMB (World Federation of Nuclear Medicine and Biology) will award a prize of \$500 USD (five hundred US dollars) to the principal author of this category.